Optimizing the use of biological therapy in patients with inflammatory bowel disease
|
|
- Benedict McLaughlin
- 5 years ago
- Views:
Transcription
1 Optimizing the use of biological therapy in patients with inflammatory bowel disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Moss, Alan C Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterology Report 3 (1): doi: /gastro/gou gastro/gou087. Published Version doi: /gastro/gou087 Citable link Terms of Use This article was downloaded from Harvard University s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at nrs.harvard.edu/urn-3:hul.instrepos:dash.current.terms-ofuse#laa
2 Gastroenterology Report, 3(1), 2015, doi: /gastro/gou087 Advance Access Publication Date: 6 January 2015 Review REVIEW Optimizing the use of biological therapy in patients with inflammatory bowel disease Alan C. Moss Division of Gastroenterology, eth Israel Deaconess Medical Center & Harvard Medical School, oston, MA, USA Corresponding author. Division of Gastroenterology, eth Israel Deaconess Medical Center, 330 rookline Avenue, oston, MA 02215, USA. Tel: þ ; Fax: þ ; amoss@bidmc.harvard.edu Abstract iological therapy revolutionized the treatment of inflammatory bowel disease (ID) during the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF), integrins or IL12/23, have been approved or are in development for both Crohn s disease (CD) and ulcerative colitis (UC). Early use of these agents taught clinicians that induction and maintenance therapy, coupled with immunomodulator agents, reduced the immunogenicity of these agents, and led to sustained remission in many patients. More recent data has demonstrated that, through dose adjustments, optimizing serum drug levels may also provide more durable maintenance of remission, and improved mucosal healing. This review examines clinical practices that may enhance clinical outcomes from biological therapy in ID. Key words: inflammatory bowel disease; biological therapy Introduction iological therapy currently refers to monoclonal antibodies directed against specific targets implicated in the pathogenesis of chronic inflammatory conditions. For inflammatory bowel disease (ID), this primarily encompasses the approved anti-tumor necrosis factor (TNF) therapies (infliximab, adalimumab, certolizumab, golimumab), but also agents approved, or under development, that target integrins (natalizumab, vedolizumab) and interleukin (IL)-12/23 (ustekinumab), amongst others. Table 1 summarizes some of the biological therapies that have been studied in clinical trials in ID. The introduction of anti-tnf agents in the United States and Europe in the late 1990s gradually led to a paradigm shift in our approach to ID therapy [1]. The deluge of studies that followed their approval provided evidence that this class of drug could induce sustained clinical remission in a cohort of patients, avoid the chronic need for steroids, reduce hospitalizations, and potentially prevent surgical interventions for complications [2]. The goal of treatment shifted from simply improving patients symptoms, to aiming for objective reversal of mucosal inflammation and prevention of long-term complications. On the down side, the use of anti-tnfs led in practice to reports of hypersensitivity reactions, reactivation of T, and lymphomas in patients receiving these agents. The unprecedented enrolment of larger cohorts of ID patients in registry studies to track adverse events led to a characterization of many diseaseand drug- related safety signals [3]. For the first time, extensive capture of health outcomes, pharmaco-economic analyses, quality-of-life measures and work productivity were undertaken to assess the impact of these diseases and their treatment on the population of patients with ID. One of the conclusions of long-term follow-up studies, in practice and clinical trials, was that many patients who initially Submitted: 6 November 2014; Revised: 6 November 2014; Accepted: 11 November 2014 VC The Author(s) Published by Oxford University Press and the Digestive Science Publishing Co. Limited. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. 63
3 64 Alan C. Moss Table 1. Examples of biologics for inflammatory bowel disease, approved and under development Name Primary target FDA-approved indication Infliximab (Remicade VR ) TNF CD, UC Adalimumab (Humira VR ) TNF CD, UC Certolizumab (Cimzia VR ) TNF CD Golimumab (Simponi VR ) TNF UC Natalizumab (Tysabri VR ) alpha-4 integrin CD Vedolizumab (Entyvio VR ) alpha-4-beta-7 integrin CD, UC Ustekinumab (Stelara VR ) IL-12/23 N/A Etrolizumab beta-7 integrin N/A Anrukinzumab IL-13 N/A FDA ¼ Food and Drug Administration; TNF ¼ tumor necrosis factor; IL ¼ interleukin; CD ¼ Crohn s disease; UC ¼ ulcerative colitis; N/A ¼ not available obtained remission with anti-tnf agents subsequently experienced reduced response over time: for example, in clinical trials, only 40% of patients were in remission at 1 year after induction, and in clinical practice less than 50% of initial responders were in remission at this time-point [4]. A review of these longterm outcomes suggests that there is clearly a population of patients who clinically respond to induction therapy and then maintain remission over time, with little need for dose adjustments; however, there is also a sizeable population of patients whose symptoms recur despite continued biological therapy. Strategies to address this problem and improve the rates of retention for this drug class have emerged in recent years [5]. Mechanisms for loss of response to iologics The recurrence of clinical symptoms after induced remission with anti-tnfs is a common one; up to 60% of patients experience recurrence of symptoms in clinical practice over time [6]. There are many reasons for this event, and these are summarized in Table 2. The relative contribution of each cause is difficult to determine in practice, but cohort studies suggest that immunogenicity and overlap functional symptoms account for most cases of loss of response [7]. Immunogenicity Immunogenicity the propensity for patients to develop anti-drug antibodies (ADAs) against the monoclonal agents develops in a proportion of patients through both thyroiddependent (high affinity, immunological memory), and thyroid independent (low affinity, occasional memory) mechanisms [8]. These ADAs are typically IgG antibodies that can impair binding of the biological agent to the target cytokine, or accelerate drug clearance by the reticulo-endothelial system (RES) [9]. When the anti-tnf antibody infliximab was initially given only intermittently in practice, up to 60% of patients developed anti-drug antibodies, and these patients were twice as likely as antibodynegative recipients to develop acute infusion reactions [10]. Since then, the use of induction and regular maintenance infusions has lowered the prevalence of anti-infliximab antibodies to 10 20% in randomized, controlled trials (RCTs) and observational cohorts [11]; in this patient population however, once they develop, ADAs are associated with a higher risk of loss of clinical response, and risk of infusions reactions [12, 13]. It has Table 2. Reasons for loss of clinical response amongst patients receiving biologics for inflammatory bowel disease Mechanism Immunogenicity (anti-drug antibodies) Enhanced drug clearance (non-immunogenic) Alternate inflammatory pathways Non-inflammatory complications (e.g. strictures) Overlap functional symptoms Concurrent infections (e.g. C. difficile or Cytomegalovirus) also recently been recognized that patients can develop transient ADAs, or persistent ADAs, and that drug-free periods lead to gradual disappearance of ADAs from circulation [14, 15]. While the factors that lead some patients to develop ADAs is only partially understood, persistently low drug serum levels have been associated with development of ADAs in some studies [16]. Overlap functional symptoms More frequent but certainly less well-characterized is the phenomenon of patients with ID experiencing non-inflammatory symptoms. These are usually described as intestinal symptoms of pain, diarrhea or rectal bleeding in the absence of objective evidence of active inflammation on endoscopy. For example, in one study, 26% of patients with inactive Crohn s disease met criteria for a diagnosis of irritable bowel syndrome (IS) while, in another study, 10% of patients with quiescent ulcerative colitis (UC) had significant on-going abdominal pain [17, 18]. In some individuals, physiological processes such as delayed gastric emptying or bile salt malabsorption may play a role even in the absence of macroscopic inflammation [19, 20]. These factors need to be considered when evaluating recurrence of symptoms, as biological therapy for is not an appropriate intervention for IS. Other processes Whilst ID manifests itself as a purely inflammatory process early on, later complications, such as strictures, fistulae, and malignancy, may lead to the development of symptoms that are unresponsive to any biological anti-cytokine therapy [9]. Small bowel strictures and their associated bacterial overgrowth can contribute to abdominal pain, bloating and diarrhea, and require mechanical correction [18]. Enteric fistulae to other abdominal compartments and organs may also lead to symptoms and a perceived loss of response to biological therapy. Strategies for optimizing the use of iological therapy The observations noted above illustrate that maintaining a sustained clinical remission with biological therapies requires attention to the many factors that could lead to relapse of symptoms. In the scenario where active inflammation has been objectively confirmed, and concurrent infections have been excluded, there are a number of therapeutic decisions that can be made to pro-actively, or reactively, enhance the efficacy of biological agents (Table 3). The evidence base for this is primarily derived from studies of infliximab, particularly with regard to serum drug levels and ADAs.
4 iological therapy in ID 65 Table 3. Proposed strategies to optimize the efficacy of biological therapies in inflammatory bowel disease Strategy Patient selection Early in disease course Administration schedule Induction & maintenance Concomitant therapy Thiopurines Methotrexate Therapeutic drug monitoring Reactive testing Proactive testing iomarker monitoring Proactive CRP measurements Patient selection iological agents were initially given only to patients with severe disease, which limited the potential long-term efficacy of these drugs. In RCTs of infliximab in Crohn s disease, for example, enrolled subjects had the disease for an average of 8 years, 51% already required surgery for complications, and a third had failed to respond to thiopurines [21]. Since Crohn s disease is a progressive condition, selecting only patients with long-standing disease for a given therapy reduces the proportion of recipients whose symptoms are caused primarily by active inflammation [22]. In contrast, post-hoc analysis of these RCTs has concluded that overall remission rates with biologics are numerically greater when administered to patients within 2 years of diagnosis [23]. Therefore, the preferred candidate for biological therapy is one with confirmed active intestinal inflammation, prior to the development of complications such as strictures. Using biologics in patients with overlap IS or mostly fibrotic disease yields lower clinical remission rates, at considerable expense to those paying for treatment [24]. Of course, not every patient with ID will require a biological therapy early after diagnosis. Selecting patients early in the course of their disease, who are at higher risk of complications, can be used to risk stratify individuals for early use of biological therapy. Clinical (age, phenotype, steroid use) and serogenetic factors have been identified, which are associated with relative risk of complications in Crohn s disease, but the relative impact of biologics on low- or high-risk patients has yet to be prospectively determined [25]. Maintenance schedules Evidence a a Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group A ¼ several high-quality studies; ¼ moderate quality: several studies with limitations; C ¼ low quality: studies with many limitations; CRP ¼ C-reactive protein The maintenance regimens tested in RCTs have confirmed that continued use of biologics is required to maintain remission in responsive patients. Episodic therapy leads, in practice, to higher rates of ADAs and infusion reactions, and lower rates of remission [10, 26]. Patients with Crohn s disease receiving scheduled infliximab had lower disease activity scores and fewer hospitalizations, but higher response rates, than patients who received episodic therapy [26]. The recommended schedule for administration (every other week, every 4 weeks or every 8 weeks) may in some cases be insufficient to maintain remission, and schedules of administration that are more frequent C C C than the approved dose are commonly used [6, 27]. A number of cohort studies have reported that these escalation strategies are able to re-capture response in up to 80% of patients who have lost response [28, 29]. Concurrent immunomodulators In some studies, the administration of concurrent immunomodulators (IMMs), such as azathioprine or methotrexate, has been associated with higher remission rates and lower rates of ADAs. Post-hoc analysis of the RCTs of anti-tnfs, and retrospective review of clinical cohorts, did not demonstrate superior efficacy of combination therapy over monotherapy in Crohn s disease [30, 31]; however, subsequent prospective trials in both CD and UC concluded that initial combination therapy was beneficial. In the SONIC (Study of iologic and Immunomodulator Naive Patients in Crohn s Disease) trial in CD, 57% of patients receiving infliximab and thiopurines were in corticosteroid-free clinical remission at week 26, as compared with 44% of those receiving infliximab alone (P ¼ 0.02) [32]. Similarly, in the SUCCESS (Efficacy and Safety of Infliximab, as Monotherapy or in Combination with Azathioprine, versus Azathioprine Monotherapy in Moderate to Severe Ulcerative Colitis) trial in UC, steroid-free remission was achieved by 40% of patients receiving infliximab or azathioprine, compared with 22% receiving infliximab alone (P ¼ 0.017) [33]. The reason for the synergistic effects of immunomodulators may be their ability to reduce the immunogenicity of biologics. In the SONIC trial, ADAs developed in less than 1% of patients receiving azathioprine and infliximab, in contrast to 15% of patients who received infliximab alone [32]. In one small case series, even post-hoc addition of an immunomodulator to a biologic could reduce ADAs, and elevate serum drug levels, in patients with CD [34]. Therapeutic drug monitoring Many observational studies have linked low serum drug levels to a higher risk of ADA development, and/or loss of response to biologics in ID [35 37]. In response, reactive measurement of ADAs and serum drug levels using Enzyme Linked Immunosorbent Assay (ELISA) assays, and appropriate adjustment of drug regimen, has been utilized in practice to optimize clinical outcomes [28, 38]. This strategy has been reported to be more cost-effective than empirical escalation of doses of biologics, with similar clinical outcomes in this setting [7, 39]. In Denmark, Steenholdt et al. concluded that individualized infliximab therapy, based on drug levels, was more cost-effective than empirical dose intensification in patients losing response to infliximab; response rates were similar (55%), but costs were 34% lower when therapeutic drug monitoring was used [7]. In the light of these findings, other groups have examined proactive adjustment of biological drug levels to prevent relapse of disease. The Trough level Adapted infliximab Treatment (TAXIT) trial from Europe enrolled patients in remission and adjusted their infliximab dose to obtain a target serum drug level; subsequently this cohort was randomized to either standard care, or continued adjustment of infliximab dose, based on drug levels. After 1 year, overall remission rates were similar in both arms (69% and 72%) [40]. A small retrospective analysis from another group reported that patients who had proactive adjustment of infliximab levels to above 5 mg/ml were less likely to discontinue infliximab than those who were not adjusted (10% vs. 31%, respectively; P ¼ 0.009) [41]. Where commercial assays for biological drug levels are not available, C-reactive protein
5 66 Alan C. Moss (CRP) and fecal calprotectin may be surrogate markers to identify patients at risk of relapse due to low drug levels [42 44]. One area of uncertainty is the drug level to aim for when using therapeutic monitoring; many studies have used different cut-offs, so it is unclear what is the ideal therapeutic range (Table 4) [16, 35, 45 54]. Conclusions There has been a steep learning curve in the optimal use of biologics in ID since The current strategies of patient selection, maintenance schedules, use of concurrent immunomodulators, and therapeutic drug monitoring have generated incremental improvements in the long-term remission rates with this class of drug. We are still not at the point where the majority of patients treated with biologics achieve sustained clinical and/or endoscopic remission. Alterations in immunological pathways over time, persistence of functional intestinal symptoms, and differences in underlying pathogenic processes may prevent this being universally achievable; however, Table 4. Drug thresholds used to categorize patients outcomes in observational studies Study Drug Threshold (lg/ml) Outcome en-assat O [35] IFX 2 Remission Drastich P [45] IFX 2 Remission Murthy S [46] IFX 2 Remission Maser EA [47] IFX 1.4 Remission Reinisch W [48] IFX 3 Remission Seow CH [49] IFX 2 Remission Steenholdt C [50] IFX 0.5 Remission Vande Casteele [16] IFX 2.2 CRP Feagan G [51] IFX 3 CRP ortlik M [52] IFX 3 CRP Mazor Y [53] ADA 5 Remission Imaeda H [54] ADA 10 CRP IFX ¼ infliximab; ADA ¼ adalimumab; CRP ¼ C-reactive protein optimal use of biologics in those who initially respond to them will certainly enhance the efficacy of this drug class in the medium term (Figure 1). Funding ACM is supported by NIH grant K23DK Conflict of interest statement. ACM has consulted for Janssen, Abbott, UC, Roche and ayer, and received research support (to IDMC) from Pfizer. References 1. Antunes O, Filippi J, Hebuterne X et al. Treatment algorithms in Crohn s: up, down or something else? est Pract Res Clin Gastroenterol 2014;28: Mandel MD, Miheller P, Mullner K et al. Have biologics changed the natural history of Crohn s disease? Dig Dis 2014; 32: Lichtenstein GR, Feagan G, Cohen RD et al. Drug therapies and the risk of malignancy in Crohn s disease: results from the TREAT Registry. Am J Gastroenterol 2014;109: Gisbert JP and Panes J. Loss of response and requirement of infliximab dose intensification in Crohn s disease: a review. Am J Gastroenterol 2009;104: Vande Casteele N, Feagan G, Gils A et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014;16: Karmiris K, Paintaud G, Noman M et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn s disease. Gastroenterology 2009;137: Steenholdt C, rynskov J, Thomsen OO et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn s disease who lose response to anti- TNF treatment: a randomised, controlled trial. Gut 2014;63: Figure 1. Strategies of biologics use in patients with inflammatory bowel disease
6 iological therapy in ID Sauerborn M, rinks V, Jiskoot W et al. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010; 31: Fasanmade AA, Adedokun OJ, lank M et al. Pharmacokinetic properties of infliximab in children and adults with Crohn s disease: a retrospective analysis of data from two phase III clinical trials. Clin Ther 2011;33: aert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn s disease. N Engl J Med 2003;348: Hanauer S, Wagner CL, ala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn s disease. Clin Gastroenterol Hepatol 2004;2: O Meara S, Nanda KS and Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm owel Dis 2014;20: Nanda KS, Cheifetz AS and Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (ID): a metaanalysis. Am J Gastroenterol 2013;108:40 7; quiz en Horin S, Mazor Y, Yanai H et al. The decline of anti-drug antibody titres after discontinuation of anti-tnfs: implications for predicting re-induction outcome in ID. Aliment Pharmacol Ther 2012;35: van de Casteele N, Cuypers L, Singh S et al. Antibodies to Infliximab can either be persistent or transient; a retrospective case-control study in ID patients treated with Infliximab maintenance therapy. Gastroenterology 2012;143: Vande CN, Gils A, Singh S et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108: Coates MD, Lahoti M, inion DG et al. Abdominal pain in ulcerative colitis. Inflamm owel Dis 2013;19: Farrokhyar F, Marshall JK, Easterbrook et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm owel Dis 2006;12: Gothe F, eigel F, Rust C et al. ile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings. J Crohns Colitis 2014;8: Nobrega AC, Ferreira R, Oliveira GJ et al. Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn s disease. MC Gastroenterol 2012;12: Hanauer S, Feagan G, Lichtenstein GR et al. Maintenance infliximab for Crohn s disease: the ACCENT I randomised trial. Lancet 2002;359: Cosnes J, Gower-Rousseau C, Seksik P et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140: Cornillie F, Hanauer S, Diamond RH et al. Can clinical, biological or pharmacological markers predict sustained response to infliximab? A retrospective analysis of ACCENT 1. Gut 2011; 60:A Liu Y, Wu EQ, ensimon AG et al. Cost per responder associated with biologic therapies for Crohn s disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012;29: eaugerie L and Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol 2012;18: Rutgeerts P, Feagan G, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn s disease. Gastroenterology 2004;126: Rostholder E, Ahmed A, Cheifetz AS et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012;35: Afif W, Loftus EV Jr, Faubion WA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105: illioud V, Sandborn WJ and Peyrin-iroulet L. Loss of response and need for adalimumab dose intensification in Crohn s disease: a systematic review. Am J Gastroenterol 2011; 106: Lichtenstein GR, Diamond RH, Wagner CL et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for ID-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30: Moss AC, Kim KJ, Fernandez-ecker N et al. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci 2010;55: Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn s disease. N Engl J Med 2010;362: Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146: e en Horin S, Waterman M, Kopylov U et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11: en-assat O, Romanova A, Lacono A et al. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn s disease. Gastroenterology 2013;144 (5 Suppl. 1):S Cesarini M, Katsanos K, Papamichael K et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis 2014;46: Colombel JF, Sandborn WJ, Allez M et al. Association etween Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients with Crohn s Disease. Clin Gastroenterol Hepatol 2014;12: e Vande Casteele N, allet V, Van Assche G et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012;61: Velayos FS, Kahn JG, Sandborn WJ et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013;11: vande Casteele N, Gils A, allet V et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in ID: final results of the TAXIT study. United European Gastroenterol J 2013;1:A Vaughn P, Martinez-Vazquez M, Patwardhan VR et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm owel Dis 2014;20:
7 68 Alan C. Moss 42. Peyrin-iroulet L, Reinisch W, Colombel JF et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn s disease in the SONIC trial. Gut 2014;63: Velayos F, Sheibani S, Lockton S et al. Prevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of ID patients. Gastroenterology 2013;144 (5 Suppl. 1):S Reinisch W, Colombel JF, Sandborn WJ et al. Infliximab serum trough level and CRP change are associated with corticosteroid-free remission in Crohn s disease: a posthoc analysis of the sonic trial. Gut 2012;61 (Suppl. 2): A Drastich P, Kozeluhova J, Jaresova M et al. Infliximab serum trough levels and deep remission in patients with ID. Gastroenterology 2011;140 (5 Suppl. 1):S Murthy S, Kevans D, Seow CH et al. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome in acute ulcerative colitis. Gastroenterology 2012;142 (5 Suppl. 1):S Maser EA, Villela R, Silverberg MS et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn s disease. Clin Gastroenterol Hepatol 2006;4: Reinisch W, Feagan G, Rutgeerts PJ et al. Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gastroenterology 2012;142 (5 Suppl. 1):S Seow CH, Newman A, Irwin SP et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59: Steenholdt C, endtzen K, rynskov J et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn s disease. Scand J Gastroenterol 2011;46: Feagan G, Singh S, Lockton S et al. Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn s disease (CD). Gastroenterology 2012;142 (5 Suppl. 1):S ortlik M, Duricova D, Malickova K et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn s disease. J Crohns Colitis 2013;7: Mazor Y, Almog R, Kopylov U et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn s disease. Aliment Pharmacol Ther 2014; 40: Imaeda H, Takahashi K, Fujimoto T et al. Accurate determination of serum adalimumab and anti-adalimumab antibodies levels during maintenance therapy for Crohn s disease. Gastroenterology 2013;144 (5 Suppl. 1):S431.
Il ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationLoss of Response to Anti-TNFs: Definition, Epidemiology, and Management
CLINICAL/NARRATIVE REVIEW Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management Citation: (2016) 7, e135; doi:10.1038/ctg.2015.63 & 2016 the American College of Gastroenterology All rights
More informationClinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
Gut and Liver, Published online September 9, 2016 ORiginal Article Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease So Yoon
More informationCorporate Medical Policy
Corporate Medical Policy Measurement of Serum Antibodies to Infliximab, Adalimumab and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: measurement_of_serum_antibodies_to_infliximab_and_adalimumab
More informationBiologic Concentration Testing in Inflammatory Bowel Disease
Biologic Concentration Testing in Inflammatory Bowel Disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Vaughn,
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationScottish Biologic Therapeutic Drug Monitoring Service Gastroenterology Guidance
Scottish Biologic Therapeutic Drug Monitoring Service Gastroenterology Guidance The purpose of this document is to provide advice and information for users of the Scottish Biologic Therapeutic Drug Monitoring
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationMaximizing the efficacy of therapies for inflammatory bowel
Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach Namita Singh, MD, and Marla C. Dubinsky, MD Dr Singh is an attending physician in the Pediatric
More informationCLINICAL INSIGHTS 01
P2 Borrowing a Treatment Paradigm From Rheumatoid Arthritis P4 Antidrug Antibody Monitoring in Practice P6 Proactive Drug Monitoring Informs Therapeutic Dose Adjustments P7 Keeping Patients in Remission
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationThe evaluation and treatment of patients with Crohn s
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:395 399 PERSPECTIVE Do Not Assume Symptoms Indicate Failure of Anti Tumor Necrosis Factor Therapy in Crohn s Disease DAVID H. BRUINING* and WILLIAM J. SANDBORN
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationMEDICAL POLICY II. III. SUBJECT: MEASUREMENT OF SERUM ANTIBODIES TO INFLIXIMAB, ADALIMUMAB, AND VEDOLIZUMAB
MEDICAL POLICY SUBJECT: MEASUREMENT OF SERUM ANTIBODIES TO INFLIXIMAB, ADALIMUMAB, AND PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationPrincipal Investigator. General Information. Certification Published on The YODA Project (
Principal Investigator First Name: William J. Last Name: Sandborn Degree: M.D. Primary Affiliation: University of California San Diego E-mail: wsandborn@ucsd.edu Phone number: 8586575284 Address: 9500
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationInfliximab Therapy in Pediatric Patients 7 Years of Age and Younger
ORIGINAL ARTICLE: GASTROENTEROLOGY Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger Judith R. Kelsen, Andrew B. Grossman, Helen Pauly-Hubbard, Kernika Gupta, Robert N. Baldassano, and
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Measurement of Serum Antibodies to Infliximab Page 1 of 8 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Measurement of Serum Antibodies to Infliximab Professional
More informationInfliximab (IFX), a chimeric monoclonal immunoglobulin G1. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance
ORIGINAL ARTICLE Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance Claire Liefferinckx, MD,* Charlotte Minsart, MSc,* Jean-François Toubeau, MSc, Anneline Cremer, MD,*,
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationPersonalized Medicine: IBD
Use of Anti-TNF Antibodies and Other Serologies for Managing IBD Christopher J. Shepela, MD, MS Assistant Professor of Medicine University of Minnesota Medical Director at Digestive Disease Center at Regions
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationProtocol. Measurement of Serum Antibodies to Infliximab and Adalimumab
Protocol Measurement of Serum Antibodies to Infliximab and Adalimumab (20484) Medical Benefit Effective Date: 04/01/15 Next Review Date: 03/19 Preauthorization No Review Dates: 11/14, 11/15, 11/16, 03/17,
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationOutline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
More informationGuide to Gastroenterology Biological Therapeutic Drug Monitoring Pathway (TDM)
Guide to Gastroenterology Biological Therapeutic Drug Monitoring Pathway (TDM) Author: Responsible Lead Consultants: Endorsing Body: Implementation Date: 01/08/2018 Version Number: 1.0 Review Date: 01/08/2020
More informationAdvances in the development of new biologics in inflammatory bowel disease
INVITED REVIEW Annals of Gastroenterology (2016) 29, 1-6 Advances in the development of new biologics in inflammatory bowel disease Bella Ungar, Uri Kopylov Sheba Medical Center, Tel Hashomer and Sackler
More informationTrends in Biologic Therapy for Crohn s Disease: Where Are We and Where Are We Going? CME
Trends in Biologic Therapy for Crohn s Disease: Where Are We and Where Are We Going? CME Uma Mahadevan-Velayos, MD Supported by independent educational grants from View this activity online at: medscape.org/column/crohns
More informationPatients with Crohn s disease respond to tumor necrosis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:654 666 A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn s Disease Who Lose Responsiveness to Infliximab
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationMedical Policy. MP Measurement of Serum Antibodies to Infliximab and Adalimumab
Medical Policy BCBSA Ref. policy: 2.04.84 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 9.01.502 Experimental / Investigational Services DISCLAIMER Our medical policies
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationTitle: Treatment persistence during therapeutic sequences with adalimumab and. and infliximab in the treatment of Crohn s. disease
Title: Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn s disease Authors: Carlos Taxonera, Pilar Robledo, Antonio Rodriguez DOI: 10.17235/reed.2017.4931/2017
More informationLevels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn s Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:421 427 Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn s Disease MATTHIAS JÜRGENS,* JESTINAH M. MAHACHIE
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationEfficacy of Adalimumab in Korean Patients with Crohn s Disease
Gut and Liver, Vol. 10, No. 2, March 2016, pp. 255-261 ORiginal Article Efficacy of Adalimumab in Korean Patients with Crohn s Disease Il Woong Sohn, Sung Tae Kim, Bun Kim, Hyun Jung Lee, Soo Jung Park,
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationCommercial Products. Medical Coverage Policy Measurement of Serum. Antibodies to Infliximab and Adalimumab
Medical Coverage Policy Measurement of Serum Antibodies to Infliximab and Adalimumab EFFECTIVE DATE: 10 02 2012 POLICY LAST UPDATED: 09 18 2018 OVERVIEW This policy documents secondary loss of response
More informationDiagnostics consultation document
National Institute for Health and Care Excellence Diagnostics consultation document Therapeutic monitoring of TNF-alpha inhibitors in Crohn s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and
More informationTechnologies scoping report
Technologies scoping report In response to an enquiry from NHS Greater Glasgow and Clyde Number 18 October 2013 What is the clinical effectiveness, cost effectiveness and implications for safety of assessing
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationUse of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
More informationCarefirst.+.V Family of health care plans
Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Measurement of Serum Antibodies to Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Measurement of Serum Antibodies to Infliximab and Adalimumab Professional
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationCrohn s
Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationEffectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn s Disease in Adults
Dig Dis Sci (2013) 58:1329 1334 DOI 10.1007/s10620-012-2374-2 ORIGINAL ARTICLE Effectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn s Disease in Adults
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More information